Cargando…

Pharmacokinetics and Drug–Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo

BACKGROUND AND OBJECTIVES: Ocedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and efficacy in clinical trials in patients with uncontrolled hypertension and stage 3b/4 chronic kidney disease. This study evaluated the involvement of cytoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ping, Liu, Jinrong, Tan, Xiaojuan, Yang, Fred, McCabe, James, Zhang, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322960/ https://www.ncbi.nlm.nih.gov/pubmed/37357226 http://dx.doi.org/10.1007/s13318-023-00837-5

Ejemplares similares

Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study
por: Bakris, George L, et al.
Publicado: (2023)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models
por: Tan, Xiaojuan, et al.
Publicado: (2020)

Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis
por: Huang, Zhenhua, et al.
Publicado: (2015)

In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China
por: Han, Renru, et al.
Publicado: (2022)

GW5074 Increases Microglial Phagocytic Activities: Potential Therapeutic Direction for Alzheimer’s Disease
por: Connor, Sarah M., et al.
Publicado: (2022)

The novel protein KBP regulates mitochondria localization by interaction with a kinesin-like protein
por: Wozniak, Marcin J, et al.
Publicado: (2005)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors
por: Kao, Chien-Chang, et al.
Publicado: (2022)

KBP interacts with SCG10, linking Goldberg–Shprintzen syndrome to microtubule dynamics and neuronal differentiation
por: Alves, Maria M., et al.
Publicado: (2010)

Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: Sindelar, Morganne, et al.
Publicado: (2023)

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
por: Sivilia, Sandra, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

The Raf-1 inhibitor GW5074 and dexamethasone suppress sidestream smoke-induced airway hyperresponsiveness in mice
por: Lei, Ying, et al.
Publicado: (2008)

The Oxindole GW-5074 Inhibits JC Polyomavirus Infection and Spread by Antagonizing the MAPK-ERK Signaling Pathway
por: Kaiserman, Jacob, et al.
Publicado: (2023)

In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies
por: Cui, Hanming, et al.
Publicado: (2016)

In vitro-in vivo Pharmacokinetic correlation model for quality assurance of antiretroviral drugs
por: Rojas Gómez, Ricardo, et al.
Publicado: (2015)

The Synergistic Cytotoxic Effects of GW5074 and Sorafenib by Impacting Mitochondrial Functions in Human Colorectal Cancer Cell Lines
por: Hu, Je-Ming, et al.
Publicado: (2022)

SH3KBP1 Promotes Glioblastoma Tumorigenesis by Activating EGFR Signaling
por: Song, Hai, et al.
Publicado: (2021)

A Novel 90-kbp Deletion of RUNX2 Associated with Cleidocranial Dysplasia
por: Zhang, Yanli, et al.
Publicado: (2022)

Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo
por: Lin, Qianmeng, et al.
Publicado: (2019)

Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches
por: Peng, Yaru, et al.
Publicado: (2021)

Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
por: Al-Enezi, Bashayer F., et al.
Publicado: (2023)

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)
por: Lepak, Alexander J, et al.
Publicado: (2018)

Identification of a Splice Variant (c.5074+3A>C) of BRCA1 by RNA Sequencing and TOPO Cloning
por: Hong, Jinyoung, et al.
Publicado: (2021)

Multiple Functions of KBP in Neural Development Underlie Brain Anomalies in Goldberg-Shprintzen Syndrome
por: Chang, Hsin-Yun, et al.
Publicado: (2019)

OpenKBP-Opt: an international and reproducible evaluation of 76 knowledge-based planning pipelines
por: Babier, Aaron, et al.
Publicado: (2022)

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanisms
por: Pfaller, Michael A, et al.
Publicado: (2021)

In Vitro–In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of Its Metabolite
por: Mircioiu, Constantin, et al.
Publicado: (2019)

A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs
por: Cicchese, Joseph M., et al.
Publicado: (2021)

Pharmacokinetic drug-drug interaction and their implication in clinical management
por: Palleria, Caterina, et al.
Publicado: (2013)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
por: Zhou, Shan, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

Pharmacokinetic Drug Interaction Studies with Enzalutamide
por: Gibbons, Jacqueline A., et al.
Publicado: (2015)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin
por: Catozzi, Simona, et al.
Publicado: (2022)

Extraction of Pharmacokinetic Evidence of Drug–Drug Interactions from the Literature
por: Kolchinsky, Artemy, et al.
Publicado: (2015)

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
por: Garg, Varun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r1it458umvds1a1v0p3a4hei9h